BIOCIDAL PROTEINS

Abstract: Biocidal proteins isolated from Mirabilis have been characterised. The proteins show a wide range of antifungal activity and are active against gram-positive bacteria. DNA encoding the proteins has been isolated and incorporated into vectors. Plants transformed with this DNA have been produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.

Description: BIOCIDAL PROTEINS This invention relates to biocidal proteins, processes for their manufacture and use, and DNA sequences coding for them. In particular, it relates to antimicrobial proteins isolated from Mirabilis. Mirabilis comprises about 60 tropical .American species, many of which are cultivated for their ornamental value as garden plants. Mirabilis jalapa is commonly known as "four o'clock" or "marvel of Peru", and has white, yellow or red flowers. The tuberous roots of M jalapa are the source of a purgative drug used as a substitute for jalap. Although plants normally grow on substrates that are extremely rich in fungal organisms, infection remains a rare event. To keep out potential invaders, plants produce a wide array of antifungal compounds, either in a constitutive or an inducible manner. The best studied of these are phytoalexins, secondary metabolites with a broad antimicrobial activity spectrum that are specifically synthesised upon perception of appropriate defence-related signal molecules. The production of phytoalexins depends on the transcriptional activation of a series of genes encoding enzymes of the phytoalexin biosynthetic pathway. During the last decade, however, it has become increasingly clear that some plant proteins can play a more direct role in the control of phytopathogenic fungi. Several classes of proteins with antifungal properties have now been identified, including chitinases, beta-l,3-glucanases, ribosome-inactivating proteins, thionins, chitin-binding lectins and zeamatins. Researchers at Japan Tobacco Inc have previously extracted an anti-viral protein from Mirabilis jalapa suspension cells (callus initially induced from leaves). and also from root and leaf tissue (Tsutomu Ikeda et al; 1987; Plant Cell Reports, 6, 216-218). This "Mirabilis anti-plant viral protein" (MAP) has a molecular weight of 24 kDa. The amino acid sequence of MAP has been determined and consists of 250 amino acids. A synthetic MAP gene of 759 base pairs has been cloned into a vector and expressed in Escherichia coli (Noriyuki Habuka et al; 1989; Journal of Biological Chemistry, 264 (12), 6629-6637). The following patents have been granted: J88061317 and US4701522 cover the Mirabilis MAP protein extract; J87027797 covers preparations of MAP by culturing callus. The following patent applications have also been filed: J63123386 on MAP obtained by cloning callus cells; J02186988 on preparations of the anti-viral protein by culturing E coli transformants; J01294694 on an anti-viral peptide (NOG-22) from Mirabilis, J01294693 on a similar synthetic peptide (NOG-53), and EP414134 on the gene encoding the anti-viral protein. In addition, Japan Tobacco have filed patent applications covering two anti-viral proteins extracted from Bougainvillea (a closely-related genus in the same family as Mirabilis): BAP-1 has a molecular weight of 33 kDa (J01272598) and BAP-2 has a molecular weight of approximately 30 kDa (J01272599). We have now purified a new class of potent antimicrobial proteins. According to the present invention, we provide antimicrobial proteins capable of being isolated from seeds of Mirabilis. In further aspects, this invention comprises a vector containing a DNA sequence coding for a protein according to the invention. The DNA may be cloned or transformed into a biological system allowing expression of the encoded protein. The invention also comprises plants transformed with recombinant DNA encoding an antimicrobial protein according to the invention. The invention also comprises a process of combatting fungi or bacteria, whereby they are exposed to the proteins according to the invention. A new class of potent antimicrobial proteins has been isolated from seeds of Mirabilis jalapa. The class includes two protein factors, hereafter called Mj-AMPl (Mirabilis jalapa - Antimicrobial Protein 1) and MJ-AMP2 (Mirabilis jalapa - Antimicrobial Protein 2) respectively. Both are dimeric proteins; Mj-AMPl consists of two 4 kDa subunits, and MJ-AMP2 consists of two 3.5 kDa subunits. Despite their origin, their primary structure differs from all other known plant proteins and instead shows homology to insect neurotoxins found in the venom of invertebrates. The amino acid sequence of Mj-AMPl and of MJ-AMP2 has been determined. These sequences enable manufacture of the protein using a standard peptide synthesiser. cDNA encoding Mj-AMPl and MJ-AMP2 has been isolated and εequenced. This DNA can be manufactured using a standard nucleic acid synthesiser, or suitable probes (derived from the known sequence) can be used to isolate the actual Mj-AMP gene(s) and control sequences from the plant genome. This genetic material can then be cloned into a biological system which allows expression of the proteins under the control of a constitutive or inducible promoter. Hence the proteins can be produced in a suitable micro-organism or cultured cell, extracted and isolated for use. Suitable micro-organisms include Escherichia coli and Pseudomonas. Suitable cells include cultured insect cells and cultured mammalian cells. The DNA can also be transformed by known methods into any plant species, so that the antimicrobial proteins are expressed within the plant . Plant cells according to the invention may be transformed with constructs of the invention according to a variety of known methods (Agrobacterium Ti plasmids, electroporation, microinjection, microprojectile gun, etc). The transformed cells may then in suitable cases be regenerated into whole plants in which the new nuclear material is stably incorporated into the genome. Both transformed monocot and dicot plants may be obtained in this way, although the latter are usually more easy to regenerate. Examples of genetically modified plants according to the present invention include: fruit such as tomatoes, mangoes, peaches, apples, pears, strawberries, bananas and melons; field crops such as canola, sunflower, tobacco, sugarbeet, small-grain cereals such as wheat, barley and rice, maize and cotton: and vegetables such as carrot, lettuce, cabbage and onion. The Mj-AMP proteins show a wide range of antifungal activity, and are also active against gram-positive bacteria. The proteins could be used as fungicides or antibiotics by application to plant parts. Their antifungal activity is salt-dependent, and may vary with the nature and concentration of the ions present in the composition. In particular, antifungal activity seems to be decreased by presence of cations. The proteins could also be used to combat fungal or bacterial disease by expression within plant bodies. The Mj-AMP proteins can be isolated and purified from Mirabilis jalapa seeds, synthesised artificially from their known amino acid sequence, or produced within a suitable micro-organism by expression of recombinant DNA. The proteins may also be expressed within a transgenic plant. The invention may be further understood by reference to the drawings, in which: Figure IA shows the gel filtration chromatogram for the antimicrobial proteins and the associated graph of fungal growth inhibition. Figure IB shows the cation exchange chromatogram for the antimicrobial proteins and the associated graph of fungal growth inhibition. Figure 2A shows the HPLC profile of purified Mj-AMPl. Figure 2B shows the HPLC profile of purified MJ-AMP2. Figure 3 shows the SDS-PAGE analysis of the purified antimicrobial proteins. Figure 4A shows the complete amino acid sequences of Mj-AMPl and MJ-AMP2; differences are indicated by arrows. Figure 4B shows the amino acid sequences of Mj-AMPl and MJ-AMP2, aligned with those of the neurotoxins. Figure 5 shows the time-dependent growth inhibition curves of fungi measured at varying concentrations of antimicrobial proteins. Figure 6 shows the nucleotide sequence and deduced amino acid sequence of clone MJ1 (Mj-AMPl). Figure 7 shows the nucleotide sequence and deduced amino acid sequence of clone MJ2 (MJ-AMP2). Figure 8 shows the construction of the expression vector pMDBl. Figure 9 shows the construction of pBinRi. Figure 10 shows the construction of the plant transformation vector pMDB2. Figure 11 shows the construction of pVTO. Figure 12 shows the construction of pVTl. Figure 13 shows the construction of the plant transformation vector pVT2. The following Examples illustrate the invention. EXAMPLE 1 Extraction of basic heat-stable proteins from Mirabilis jalapa seeds. One kg of M jalapa seeds (purchased from Chiltern Seeds, Ulverston, Cumbria, UK) was ground in a coffee mill and the resulting meal was extracted for 2 hours at 4°C with 2 litres of an ice-cold extraction buffer containing 10 mM NaH 2 P0 4 , 15 mM Na 2 HP0 4 , 100 mM KCl, 2 mM EDTA, 2 mM thiourea, 1 mM PMSF and 1 mg/1 leupeptin. The homogenate was squeezed through cheesecloth and clarified by centrifugation (5 min at 5,000 x g). Solid ammonium sulphate was added to the supernatant to obtain 35% relative saturation and the precipitate formed after standing for 1 hour at room temperature was removed by centrifugation (10 min at 5,000 x g). The supernatant was adjusted to 65% relative ammonium sulphate saturation and the precipitate formed overnight at room temperature collected by centrifugation (30 min at 5,000 x g). After redissolving the pellet in 300 ml 10 mM sodium phosphate buffer (pH 6) the solution was heated at 75°C for 10 min. The coagulated insoluble material was discarded after centrifugation (20 min at 5,000 x g) and the supernatant was dialyzed extensively against distilled water using benzoylated cellulose tubing (Sigma) with a molecular weight cut off of 2,000 Da. After dialysis the solution was adjusted to 50 mM Tris-HCl (pH 9) by addition of the ten-fold concentrated buffer, and subsequently passed over a Q-Sepharose Fast Flow (Pharmacia) column (12 x 5 cm) in equilibrium with 50 mM Tris-HCl (pH 9). The proteins in the unbound fraction were precipitated by addition of ammonium sulphate to 75% relative saturation. The precipitate was collected by centrifugation (20 min at 5,000 x g) and the pellet redissolved in 15 ml phosphate buffered saline (PBS). This material represents the basic /15691 heat-stable protein fraction of M jalapa seeds, and was the starting material used for the isolation and purification of the M jalapa antimicrobial proteins. EXAMPLE 2 Antifungal activity assay. Antifungal activity was measured by microspectrophotometry as previously described (Broekaert, WF et al; 1990; FEMS Microbiol Lett, 69, 55-60). Routinely, tests were performed with 20 μl of a (filter-sterilized) test solution and 80 μl of a fungal 4 spore suspension (2 x 10 spores/ml) in half strength Potato Dextrose Broth (Difco). Control microcultures contained 20 μl of (sterile) distilled water and 80 μl of the fungal spore suspension. Unless otherwise stated the test organism was Fusarium culmorum and incubation was done at 25°C for 48 hours. Percent growth inhibition is defined as 100 times the ratio of the corrected absorbance of the control microculture minus the corrected absorbance of the test microculture over the corrected absorbance at 595 nm of the control microculture. The corrected absorbance values equal the absorbance at 595 nm of the culture measured after 48 hours minus the absorbance at 595 nm measured after 30 min. Values of growth inhibition lower than 10% are not indicated on the chromatograms. EXAMPLE 3 Purification of antimicrobial proteins from M jalapa seeds. The starting material for the isolation of the M jalapa antimicrobial proteins was the basic heat-stable protein fraction extracted from the mature seeds. Figure IA illustrates how the antimicrobial proteins were purified by gel filtration chromatography. One ml fractions were applied on a Superose-12 column (50 x 1.6 cm) previously equilibrated with PBS. Running buffer was PBS and the flow rate 1 ml/min. The eluate was monitored for absorbance at 280 nm and collected in 2.5 ml fractions of which 2 μl was used in the microspectrophotometric antifungal activity assay described in Example 2 (results shown in the upper panel of Figure IA) . Upon fractionation, the mixture resolved into three peaks, whereby the antifungal activity coeluted with the most retarded peak. The fractions containing antifungal activity (material from this peak) were pooled, dialyzed against 50 mM Na-MES (pH5) and subjected to cation exchange chromatography. Active fractions combined from three parallel gel filtration chromatographic runs were loaded on a S-Sepharose High Performance column (10 x 1.6 cm) in equilibrium with 50 mM Na-MES (pH 5). The column was eluted at 3 ml/min with a linear gradient from 0 to 150 mM NaCl in 50 mM Na-MES (pH 5), 450ml total. The eluate was monitored for protein by measurement of the absorbance at 280 nm (results shown in the lower panel of Figure IB) and collected in 15 ml fractions of which 2 μl was tested in the microspectrophotometric antifungal activity assay (results shown in the upper panel of Figure IB). No antifungal activity was found in the unbound fraction. Application of a linear NaCl gradient allowed the separation of two factors with antifungal activity. The first factor, called Mj-AMPl (Mirabilis jalapa - Antimicrobial Protein 1) eluted as a major peak around 50 mM NaCl, whereas the second factor, designated analogously as MJ-AMP2, eluted at 100 mM NaCl. The purity of the isolated antimicrobial factors was verified by reverse-phase chromatography. HPLC profiles of the purified Mj-AMPs were obtained by loading two hundred μg amounts of Mj-AMPl and of M -AMP2 on a Pep-S (porous silica - S I R c °l uπιn (25 x 0.4 cm) (Pharmacia) in equilibrium with 0.1% TFA. The column was eluted at 1 ml/min with the following gradients (solvent B is methanol containing 0.1 % TFA): 0-1 min, 0% B; 1-3 min, 0-30% B; 3-23 min, 30-80% B; 23-25 min, 80-100% B. The eluate was monitored for protein by measurement of the absorption at 280 nm. One ml fractions of the eluate were collected, freeze-dried, and finally dissolved in 100 μl distilled water of which 20 μl was used in a microspectrophotometric antifungal activity assay. Chromatography was performed on a Waters 600 HPLC station. Figure 2A and Figure 2B show the HPLC profiles of purified Mj-AMPl and MJ-AMP2 respectively. The lower panels show monitoring of the eluate for protein by measurement of the absorption at 280 nm. Results of the microspectrophotometric antifungal activity assay are shown in the upper panels. Both Mj-AMPl and MJ-AMP2 yielded single, well resolved, major peaks that coeluted exactly with the antifungal activity. EXAMPLE 4 Molecular structure of the purified antimicrobial proteins. The molecular structure of the Mj-.AMPs was further analysed. Electrophoresis was performed on precast commercial gels (PhastGel High Density from Pharmacia) using a PhastSystem (Pharmacia) electrophoresis apparatus. The sample buffer contained 200 mM Tris-HCl (pH 8.3), 1% (w/v) SDS, 1 mM EDTA, 0.005% bromophenol blue and, unless otherwise stated, 1% (w/v) dithiothreitol (DTT). Silver staining of proteins in the gel was done according to Development Technique File no 210 of PhastSystem (Pharmacia LKB Biotechnology, Uppsala, Sweden), and diffusion blotting followed by silver staining of the blots was performed as described in Development Technique File no 222 of PhastSystem. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) of the unreduced Mj-AMPs failed to reveal the presence of proteins. However, when nitro-cellulose blots were prepared from the gels, Mj-AMPl and MJ-AMP2 appeared on the blots as single bands with molecular weights of 8 kDa and 7 kDa, respectively. Unreduced protein samples (200 ng) were dissolved in sample buffer without DTT, separated on PhastGel High Density (Pharmacia), blotted on to nitrocellulose and silver-stained on the blot. Myoglobin fragments were used as molecular weight markers. The reduced Mj-AMPs could be stained directly in the gel upon SDS-PAGE, showing rather diffuse bands in the apparent molecular weight zone of 3 to 4 kDa. Protein samples (200 ng) were reduced in sample buffer containing DTT, separated on PhastGel High Density and silver-stained in the gel. Figure 3 shows the SDS-PAGE analysis of the purified antimicrobial proteins. Panel A of Figure 3 shows the unreduced protein samples: lane 1, MJ-AMP2; lane 2, Mj-AMPl; lane R, myoglobin fragments with molecular weights indicated in kDa at the right of panel B. Panel B of Figure 3 shows the reduced protein samples: lane 1, MJ-AMP2; lane 2, Mj-AMPl; lane R, myoglobin fragments as molecular weight markers. It appears therefore that the antimicrobial factors are dimeric proteins stabilised by disulphide bridges, each comprised of two identical subunits (about 4 kDa and 3.5 kDa for Mj-AMPl and MJ-AMP2, respectively). Attempts to determine the molecular weight of the native Mj-AMPs by gel filtration on either Superose-12 or Superdex yielded clearly underestimated values (between 1 and 2 kDa), most probably due to interactions with the gel matrices. Periodic Acid Schiff's (PAS) staining of reduced /15691 Mj-AMPs separated by SDS-PAGE was negative, suggesting that their polypeptides are non-glycosylated. PAS staining for glycoproteins was done by the method of Zacharius, RM et al (1969; Anal Biochem, 30, 148-152) using ovalbumin (3.2% carbohydrate) as a positive control sample. The pi values of Mj-AMPl and MJ-AMP2 were determined by isoelectric focusing and found to be about 10.5 for both proteins. Isoelectric focussing was done on precast Immobiline Dry Strips (Pharmacia) using marker proteins in the pi range from 4.7 to 10.6 (Pharmacia). All cysteine residues of MJ-AMP2 appeared to participate in disulphide bonds, as unreduced Mj-AMP2 did not contain free thiol groups. Likewise, Mj-AMPl only reacted with thiol reagents in its reduced but not in its unreduced state. Thiol group determination was done by the dithionitrobenzoic acid method of Ellman, GL (1959; Arch Biochem Biophys, 82, 70-74) using 10 nmol of protein. Reduced protein samples were prepared by reaction with 10 mM DTT for 1 hour at 45°C followed by extensive dialysis against distilled water using benzoylated cellulose tubing (Sigma) with a molecular weight cut off of 2 kDa. EXAMPLE 5 Amino acid sequencing of the Mj-AMPs. Cysteine residues of antimicrobial proteins were modified by S-carboxyamidomethylation as follows: 100 μg amounts of purified proteins were dissolved in 150 μl 0.3 M Tris-HCl (pH 8.6) containing 30 mM DTT and reacted for 1 hour at 45°C. Iodoacetamide was added to a final concentration of 100 mM and the mixture was kept in the dark at 37°C for 1 hour. The reaction was finally quenched by addition of DTT to a final concentration of 100 mM and allowed to react for an additional hour at 37°C. Desalting was done by High Performance Liquid Chromatography (HPLC) on a Pep-S (porous silica C C I Q * 1 (Pharmacia) column (25 x 0.4 cm). The carboxyamidomethylated proteins were recovered by eluting the column with a linear gradient from 0.1% trifluoroacetic acid (TFA) to 2-propanol containing 0.1% TFA. The resulting protein fractions were subjected to amino acid sequence analysis in a 477A Protein Sequencer (Applied Biosystems) with on-line detection of phenylthiohydantoin amino acid derivatives in a 120A Analyser (Applied Biosystems). Sequence data were obtained for 37 residues of Mj-AMPl, after treatment with pyroglutamate amino peptidase (to remove a blocked N-terminal residue) and with trypsin (to generate internal peptides). The molecular mass of Mj-AMPl was verified by fast atom bombardment mass spectroscopy and found to be 3976 daltons, corresponding exactly to the predicted molecular mass. The sequence was homologous with MJ-AMP2, featuring differences at amino acid 28 (an asparagine replaced by a glycine), amino acid 33 (a valine replaced by a tyrosine), and amino acid 35 (an arginine replaced by a lysine). A glutamine at amino acid 1 was further identified in Mj-AMPl. Both peptides contain 6 cysteine residues. Figure 4A shows the complete amino acid sequences of Mj-AMPl and MJ-AMP2; differences are indicated by arrows. The Mj-AMP sequences were found to be homologous to neurotoxins found in the venom of invertebrates including yt/-agatoxins from the spider Agelenopsis aperta (Skinner, WS et al; 1989; J Biol Chem, 264, 2150-2155), conotoxins from marine snail Conus sp. (Olivera, BM, et al; 1985, Science, 230, 1338- 1343), toxins from the Buthotus scorpion (Fazal A et al, 1989, FEBS Letters 257 260-2), and curtatoxins (Stapleton et al, 1990, J Biol Chem, 265(4), 2054-2059). Figure 4B shows the amino acid sequences of Mj-AMPl and MJ-AMP2, aligned with those of the neurotoxins. Homologous amino acids are boxed. Dashes indicate gaps introduced for optimal alignment of the sequences. EXAMPLE 6 Stability of the antifungal activity of the Mj-AMPs. Table 1 summarises the results of further testing of the stability of the antifungal activity of the Mj-.AMPs. Tests for antifungal activity were performed with 20 μl samples diluted five-fold with growth medium containing 4 Fusarium culmorum spores (2 x 10 spores/ml), according to the assay method given in Example 2. Control samples contained either Mj-AMPl at 500 tg/ml or MJ-AMP2 at 100 g/ml in 10 mM sodium phosphate buffer (pH 7). Reduction was done by addition of DTT at 2.5 mM followed by incubation at 37 β C for 2 hours. pH stability was tested in the following buffers: 20 mM glycine-HCl (pH 2 and 3); 20 mM diethanolamine-HCl (pH 10); and 20 mM glycine-NaOH (pH 11). After 1 hour of incubation in the appropriate buffers the samples were dialyzed for 16 hours against 10 mM sodium phosphate buffer (pH 7). For digestions, proteases were added at 100 /g/ml and incubated at 37°C for 16 hours. TABLE 1 Stability of the antifungal activity of Mj-AMPs Treatment Relative antifungal activity (shown as % of control activity) Mj-AMPl MJ-AMP2 Control 100 100 Reduction < 6 < 3 80°C, 10 min 100 100 90°C, 10 min 100 100 100°C 10 min 100 100 pH 2, 60 min 100 100 pH 3, 60 min 100 100 pH 10, 60 min 100 100 pH 11, 60 min 100 100 Pronase E digestion 50 25 Chymotrypsin digestion 12 50 Trypsin digestion 75 100 Proteinase K digestion 100 100 After reduction of their disulphide bonds, Mj-AMPs completely lost their antifungal activity against _ culmorum. The activity of the native proteins, however, was not affected by heat treatments at up to 100°C for 10 minutes, and was stable over the pH range of 2 to 11. Mj-AMPl was sensitive to the protease chymotrypsin, but resisted almost completely digestion by pronase E, trypsin and proteinase K, whereas MJ-AMP2 was most sensitive to pronase E treatment. E.XAMPLE 7 Antifungal potency of the Mj-AMPs. The antifungal potency of the Mj-AMPs was examined on 13 different plant pathogenic fungi, and compared to that of two known antifungal proteins, Urtica dioica agglutinin or UDA (Broekaert, WF et al; 1989; Science, 245, 1100-1102) and β-purothionin (Hernandez-Lucas, C et al; 1974; Appl Microbiol, 28, 165-168). Fungi were grown on six cereal agar under white fluorescent light and spores were harvested and stored as previously described (Broekaert, WF et al; 1990; FEMS Microbiol Lett, 69, 55-60). The following fungal strains were used: Alternaria brassicola MUCL 20297, Ascochyta pisi MUCL 30164, Botrytis cinerea MUCL 30158, Colletotrichum lindemuthianum MUCL 9577, Fusarium culmorum IMI 180420, Fusarium oxysporum f.sp. pisi IMI 236441, Fusarium oxysporum f.sp. lycopersici MUCL 909, Nectria haematococca Collection Van Etten 160-2-2, Phoma betae MUCL 9916, Pyrenophora tritici-repentis MUCL 30217, Pyricularia oryzae MUCL 30166, Venturia inae ualis MUCL 15927, Verticillium dahliae MUCL 19210. UDA was isolated from stinging nettle (Urtica dioica) rhizomes as previously described (Peumans, WJ et al; 1983; FEBS Lett, 177, 99-103). The β-purothionin was purified from wheat endosperm by the method of Redman, DG and Fisher, N (1969; J Sci Fd Agric, 20, 427-432). Table 2 summarises the results. Serial dilutions of Mj-AMPl, MJ-AMP2, UDA and β-purothionin were applied to fungi and the percent growth inhibition measured by microspectrophotometry (as described in Example 2). The concentration required for 50% growth inhibition after 48 hours of incubation was taken as the ICJ- Q value, which was calculated from the dose-response curves. The IC ς0 of the slow growing fungus Venturia inaequalis was measured after 10 days of incubation. The concentrations required for 50% inhibition of fungal growth after 48 hours of incubation (IC ςo ) varied from 6 to 300 yt/g/ml for MJ-.AMP1, from 0.5 to 20 jtvg/ml for MJ-AMP2, from 0.5 to 15 yt/g/ml for β-purothionin, and from 20 to over 1,000 g/ml for UDA depending on the test organism. On an average basis the obtained antifungal activity series is as follows: MJ-AMP2 ■ β-purothionin > Mj-AMPl > UDA. Some fungi, such as B cinerea, C lindemuthianum and V inaequalis, are clearly more sensitive to MJ-.AMP2 than to β-purothionin. Conversely, the latter protein is most effective in deterring growth of other fungi such as F oxysporum f.sp. pisi and P_ tritici-repentis. With all tested antifungal proteins, the extent of growth inhibition tended to decrease as the incubation time increased. For instance, the IC 50 value of Mj-AMPl on C lindemuthianum rose from 6 /g/ml after 48 hours of incubation to 12 /g/ml after 72 hours. The time-dependent drop in antifungal activity, however, was less pronounced for MJ-AMP2 and β-purothionin than for Mj-AMPl or UDA. ALso, MJ-AMP2 and β-purothionin characteristically produced steeper dose-response curves than Mj-AMPl or UDA. Figure 5 shows the time-dependent growth inhibition curves of the fungi Colletotrichum lindemuthianum (panels A, C, E, G) and Alternaria brassicola (panels B, D, F, H) measured at varying concentrations of the following proteins: Mj-AMPl (panels A and B), MJ-AMP2 (panels C and D), UDA (panels E and F), and β-purothionin (panels G and H). The percent growth inhibition was recorded after 48 h ( • t ) , after 60 h ( 0 0 ) or after 72 h ( * « ) . TABLE 2 Antifungal activity of Mj-AMPs and other antifungal proteins on different phytopathogenic fungi Fungus Mj-AMPl β-purothionin 20 3 200 3 60 12 6 15 30 1 15 0.5 200 ND 15 1 25 4 300 4 6 ND 12 0.5 12 * ND = not determined EXAMPLE 8 .Antifungal activity of the Mj—AMPs against foliar diseases: in vivo test. The basic heat-stable protein fraction from Mirabilis jalapa and a pure sample of Mj-AMPl were tested against foliar fungal diseases of plants using the following technique. The plants were grown in John Innes Potting Compost (No 1 or 2) in 4 cm diameter mini-pots. The protein preparation was formulated immediately prior to use by dissolving in sterile deionised water and diluting to the appropriate concentration. It is assumed that the protein extract contains approximately 1% active ingredient. A pure sample of Mj-AMPl was similarly prepared. The formulations were applied to the plants as a foliar spray. The spray was applied to maximum discrete droplet retention. Tween 20, to give a final concentration of 0.05%, was added when the spray was applied to cereals. The protein preparation was applied to the foliage (by spraying) one or two days before the plant was inoculated with the disease (protectant application). Foliar pathogens were applied by spray as spore suspensions on to the leaves of test plants. After inoculation, the plants were put into an appropriate environment to allow infection to proceed and then incubated until the disease was ready for assessment. The period between inoculation and assessment varied from four to fourteen days according to the disease and environment. Results are shown in Table 3 for the three fungal pathogens: Septoria nodorum (Fungi Imperfecti) tested on wheat, Plasmopara viticola (Phycomycete) tested on grapevine, and Cercospora beticola tested on sugarbeet. The disease control was recorded by the following grading: 4 « no disease; 3 = trace - 5% of disease on untreated 15691 plants; 2 - 6-25% of disease on untreated plants; 1 - 26-60% of disease on untreated plants; 0 - 61-100% of disease on untreated plants. TABLE 3 Control of fungal diseases in vivo by Mirabilis proteins TEST ORGANISM FOLIAR SPRAY CONC. CRUDE PROTEIN EXTRACT Mj-AMPl 10mg/ml 2.5mg/ml Untreated 100 g/ml control These results confirm that the Mirabilis protein extract or the purified Mj-AMPl peptide can act as a fungicide in vivo when applied as a foliar spray. EXAMPLE 9 .Antifungal activity of the Mj-AMPs against foliar diseases: in vitro test. The protein preparation as defined in Example 8 was also tested for activity against a spectrum of fungal pathogens in vitro. A measured aliquot of the formulated material was dispersed in an agar medium (Petris minimal medium, consisting of a salts solution of 2g Ca(N0 3 ) 2 , 0.725g MgS0 4 , 0.725g KH 2 P0 4 , 0.6g KCl, 17.2g NaH 2 P0 4 , 17.725g Na 2 HP0 4 in 1000ml of water, plus an agar solution consisting of lOg Technical Agar no 3 (Oxoid) and 50g sucrose in 800ml water). The agar was subsequently inoculated with a range of pathogens using either spore suspensions or mycelial plugs. The agar plates were then inoculated for a period of up to 5 days before assessment. Results are shown in Table 4. The disease control was recorded by the following grading: 4 ■ no growth of pathogen (complete inhibition); 3 « trace growth of pathogen; 2 « restricted/moderate growth of pathogen; 0 - no inhibition of pathogen; M» missing result. TABLE 4 Control of fungal diseases in vitro by Mirabilis protein extract TEST ORGANISM CONCENTRATION OF CRUDE PROTEIN EXTRACT 10 mg/ml 2.5 mg/ml Untreated contro Penicillium pinophilum 4 2 0 Aureobasidium pullulans 4 2 0 Aspergillus niger 2 3 0 Penicillium digitatum 4 4 0 Colletotrichum musae 2 2 0 Botrytis cinerea 4 3 0 Fusarium culmorum 4 4 0 Geotrichiu candidum 4 3 0 Verticilliu albo-atrum M 2 0 The protein extract shows a broad spectrum of antifungal activity at both rates tested. EXAMPLE 10 Inhibitory activity of Mj-AMPs against yeast. The inhibitory activity of Mj-AMPs against yeast, Saccharomyces cerevisiae was tested. The results shown in Table 5 indicate that Mj-AMPs do inhibit the growth of yeast at concentrations of 500 μg/n . or above. TABLE 5 Inhibitory activity of purified Mj-AMPs CONCENTRATION ( /g/ml) without Ca/K with Ca/K 500 5l) 5 ~ 500 50 5 MJ-.AMP1 +++ +++ + +++ - - MJ-AMP2 +++ +++ +++ +++ +++ - +++ : complete inhibition + : some inhibition - : no inhibition E.XAMPLE 11 .Antibacterial activity of the Mj-AMPs: in vitro test. The antibacterial activity of the Mj-.AMPs was tested against a range of gram-positive and gram-negative bacteria: Bacillus megaterium, Sarcina lutea, Escherichia /15691 PCI7GB9 coli and Erwinia carotovora. β-purothionin and UDA were also tested for comparison (see Example 7). Tests were performed in soft agarose medium containing 1% tryptone and, with or without ImM CaCl 2 and 50mM KCl. Absorbance, 595nm, of the culture was measured after 48 hours. Results are shown in Table 6. TABLE 6 Antibacterial activity of Mj-AMPs , β-purothionin and UDA The results show that while the Mj-AMPs appear to have no activity against gram-negative bacteria, they do inhibit growth of gram-positive bacteria. EXAMPLE 12 Molecular cloning and sequence of the Mj-AMP cDNAs. Fully matured seeds of Mirabilis jalapa were collected from outdoor grown plants, immediately frozen in liquid nitrogen and stored at -80°C. Total RNA was extracted from 15g of pulverised seeds by the method of De Vries et al (1988, Plant Molecular Biology Manual, B6, 1-13). Poly (A) RNA was purified by oligo (dT)-cellulose affinity chromatography as described by Silflow et al (1979, Biochemistry, 18, 2725-2731) yielding about lOg of poly (A) RNA. Double-stranded cDNAs were prepared from 2 g of poly (A) + RNA according to Gubler and Hoffman (1983, Gene, 25, 263-269) using the cDNA Synthesis System Plus of Ame sham. The cDNAs were cloned into the λgtlO phage vector (Amersham) after ligation to EcoRI linkers (Amersham) according to the manufacturer's instructions. Phage DNA was packaged iτι vitro with the Gigapack II Gold packaging system (Stratagene) . A DNA probe for screening of the cDNA library was produced by polymerase chain reaction (PCR) as follows. Two degenerate oligonucleotides were synthesised: OWB3 (5'TGYATHGGNAAYGGNGGNMGNTG) and OWB4 (5'ACNCCRTANCCYTGRTTNGGYTG) . OWB3 corresponds to amino acids 1 to 8 of MJ-AMP2 and has a sense orientation. OWB4 corresponds to amino acids 25 to 32 of MJ-AMP2 and has an antisense orientation. PCR was performed with the Taq polymerase under standard conditions (Sambroσk et al, 1989, Molecular Cloning, Cold Spring Harbour Lab Press) using OWB3 and OWB4 as amplimers and 25ng of cDNA as target DNA. The temperature programme included an initial step at 94°C for 5 min, 30 cycles (94°C for 1 min; 45°C for 2 min; 72°C for 3 min) and a final step at 72°C for 10 min. The 100 bp PCR amplification product was purified on a 3% agarose (NuSieve, FMC) gel and reamplified by PCR under the same conditions except that the reaction mixtures contained 130 /M dTTP and 70 μl digoxigenin-11-dUTP instead of 200 μli dTTP. The digoxigenin-labelled PCR product was purified on a 3% NuSieve agarose gel. About 100,000 plaque forming units of the λgtlO cDNA library were screened with the digoxigenin-labelled PCR product by ^n situ plaque hybridisation using nylon membranes (Hybond -N, Amersham) . Membranes were air-dried and DNA was crosslinked on the membranes under UV light 2 (0.15 J/cm ). Hybridisation was performed for 16 hours at 68°C in 5 x SSC, 1% blocking reagent (Boehringer Mannheim), 0.1% N-lauroylsarcosine, 0.02% sodium dodecylsulphate containing 10 ng/ml of heat denatured digoxigenin-labelled probe. Non-specifically bound probe was removed by rinsing twice for 5 min in 2 x SSC/0.1% SDS at 25°C and twice for 15 min in 0.1 x SSC/0.1% SDS at 68 β C. Detection of the probe was done using anti-digoxigenin antibodies linked to alkaline phosphatase (Boehringer Mannheim) and its substrate 5-bromo-4-chloro-3-indolyl phosphate (Boehringer Mannheim) according to the manufacturer's instructions. Positive plaques were purified by two additional screening rounds with the same probe under the same conditions. Inserts from purified plaques were subcloned into the EcoRI site of pEMBLlδ (Dente et al, 1983, Nucl Acid Res, 11, 1145-1155). Nucleotide sequencing was done with an ALF automated sequencer (Pharmacia) using fluoresceine-labelled M13 forward and reverse primers (Pharmacia). Sequence analysis was performed by the PC-gene software (Intelligenetics) . Inserts from two positive clones, MJl and MJ2 were subjected to nucleotide sequence analysis. MJl is 360 nucleotides in length and appears to be truncated at its 5' end. The coding region contains 61 amino acids including the 37 amino acids of Mj-AMPl at the carboxy-terminal part. Again, the amino-terminal part (24 amino acids) has all the features of a signal peptide but is truncated since it lacks an initial methionine. The 3' untranslated region is 172 nucleotides long and includes a putative polyadenylation signal (AATAAG) at position 326 and a 12-nucleotide poly (A) tail. MJ2 is 433 nucleotides long and contains an open reading frame of 63 amino acids. The 36 carboxy-terminal amino acids correspond exactly to the amino acid sequence of MJ-AMP2, whereas the 27 amino-terminal amino acids have a predicted signal peptide structure obeying the (-l,-3)-rule (von Heijne, 1985, Mol Biol, 184, 99-105). MJ2 has 34-nucleotide and 210-nucleotide untranslated regions at the 5' and 3' end, respectively. A putative polyadenylation signal (AATAAG) is located at position 399 and is followed 11 nucleotides downstream by an 18-nucleotide poly (A) tail. Figures 6 and 7 show the nucleotide sequences and deduced amino acid sequences of clones MJl and MJ2, respectively. The open boxes correspond to the amino acid sequence of the mature Mj-AMPs. Stop codons are marked with asterisks and the potential polyadenylation sites are underlined. EXMIPLE 13 Construction of the expression vector pMDBl. The insert MJ2 (containing the MJ-.AMP2 sequence) was removed by BamHI digestion from the pEMBL18 + vector and sub-cloned in a BamHI site of the expression vector pFAJ3002. pFAJ3002 is a modification of the expression vector pFFl9 (Zimmermans et al, 1990, J Biotechnology, 14, 333-344) comprising a Hindlll substitution of an EcoRI site and a CaMV35S double enhancer sequence. A clone comprising MJ2 in a sense orientation was designated pMDBl: its construction is shown in Figure 8. EXAMPLE 14 Construction of the plant transformation vector pMDB2 for extracellular expression of MJ-AMP2. The MJ2 CaMV35S promoter insert was Hindlll digested from pMDBl and subcloned into the unique Hindlll site of pBinRi. pBinRi is a modified version of the plant transformation vector pBinl9 (Bevan, 1984, Nucleic Acids Research, 12:22, 8711-8721) wherein the unique EcoRl and Hindlll sites are switched and a wild type npt II gene is included as illustrated in figure 9. The new plant transformation vector is designated pMDB2 and is illustrated in figure 10. EXAMPLE 15 Construction of the plant transformation vector pVT2 for vacuolar expression of MJ-AMP2. A construct was made to ensure the proper processing and transport of MJ-AMP2 to the vacuoles of transgenic plants. A nucleotide sequence coding for a 15 amino acid propeptide (Bednarek S.Y. et al, 1991, Plant Cell 3, 1195-1206) with an additional amino acid to facilitate cleavage of the propeptide from the mature protein was synthesised. Using PCR techniques, the new synthetic sequence for the propeptide was linked to the plant cDNA encoding the MJ-AMP2 peptide and signal peptide (MJ2) to give the insert designated VT, containing a Kpnl site at the 5' end and a Pstl site at the 3' end. The KpnI-PstI fragment (generated by PCR) was cloned in the KpnI-PstI site of pEMBLl8 + to give pVTO, shown in Figure 11. The KpnI-PstI fragment of pVTO was cloned in the KpnI-PstI sites of the plant expression cassette pFFl9 to give pVTl, shown in Figure 12. The Hindlll-EcoRI fragment of pVTl was then cloned in the Hindlll-EcoRI site of pBinRi to give the plant transformation vector designated pVT2, shown in Figure 13. EXAMPLE 16 Plant Transformation. Agrobacterium strain LBA4404 ACH5 IpAL4404] was transformed to contain either of the vectors pMDB2 or pVT2, using the method of de Framond A et al (Biotechnology, 1, 262-9). Tobacco transformation was carried out using leaf discs of Nicotiana tabacum Samsun based on the method of Hozsch RB et al (1985, Science, 227, 1229-31) and co-culturing with Agrobacterium strains containing pMDB2 or pVT2. Co-cultivation was carried out under selection pressure of 100 g/ml kanamycin. Transgenic plants (transformed with pMDB2 or pVT2) were regenerated. These transgenic plants are being analysed for expression of the newly introduced genes using standard Western blotting techniques. Plants capable of constitutive expression of the introduced genes will be selected and self-pollinated to give seed. Fl seedlings of the transgenic plants will be further analysed.

Claims: CLAIMS 1 Antimicrobial proteins isolated from Mirabilis seed. 2 The pure protein Mj-AMPl, capable of being isolated from Mirabilis seed. 3 The pure protein MJ-AMP2, capable of being isolated from Mirabilis seed. 4 Pure proteins having the amino acid sequence of proteins as claimed in any of claims 1-3. 5 Protein as claimed in claim 4 which is synthetic. 6 A recombinant DNA sequence coding for a protein as claimed in any of claims 1-5. 7 A vector containing a DNA sequence as claimed in claim 6. 8 A vector as claimed in claim 7 containing a DNA sequence isolated from a plant genome. 9 A biological system including DNA as claimed in claim 6 which allows expression of the encoded protein. 10 A biological system as claimed in claim 9 which is a micro-organism. 11 A biological system as claimed in claim 9 which is a plant. Plants transformed with recombinant DNA as claimed in claim 6. Plants transformed with a recombinant DNA sequence coding for the protein Mj-AMPl. Plants transformed with a recombinant DNA sequence coding for the protein MJ-AMP2. Protein derived from expression of the DNA as claimed in claim 6. Antimicrobial protein produced by expression of recombinant DNA within plants as claimed in any of claims 12-14. An antimicrobial composition containing one or more of the proteins as claimed in any of claims 1-5 or claims 15-16. A process of combating fungi or bacteria which comprises exposing them to the proteins or compositions as claimed in any of claims 1-5 or claims 15-17. An extraction process for producing biocidally active proteins as claimed in any of claims 1-5 or claims 15-16 from organic material containing them which comprises submitting the organic material to maceration and solvent extraction. An extraction process as claimed in claim 19 where the protein is subsequently purified by centrifugation, chromatography and dialysis . An extraction process as claimed in either claim 19 or claim 20 where the organic matter comprises seeds of Mirabilis. An extraction process as claimed in either claim 19 or claim 20 where the organic matter comprises a micro-organism as claimed in claim 10.

Inventors: BROEKAERT WILLEM FRANS, CAMMUE BRUNO PHILIPPE ANGELO, DE BOLLE MIGUEL, REES SARAH BRONWEN, VANDERLEYDEN JOZEF, BROEKAERT, WILLEM, FRANS, CAMMUE, BRUNO, PHILIPPE, ANGELO, DE BOLLE, MIGUEL, REES, SARAH, BRONWEN, VANDERLEYDEN, JOZEF
Applicants: ICI PLC, IMPERIAL CHEMICAL INDUSTRIES PLC
Application year: 1992
Main classification: C12N15
IPC codes: A01H5, A01N65, A61K38, A61P31, C07K14, C12N1, C12N5, C12N15, C12P21